888952-52-1

Upstream product

• 321-69-7 5-fluoroisatoic anhydride 
• 2924-15-4 (2-fluorophenyl)hydrazine hydrochloride 
• 2368-80-1 2-fluorophenylhydrazine 
• 446-08-2 2-amino-5-fluorobenzoic acid 
• 1358761-75-7 2-chloro-5-fluorobenzoic acid N'-2-fluorophenylhydrazide 
• 1358761-74-6 C₁₃H₉BrF₂N₂O 
• 2252-50-8 2-chloro-5-fluoro-benzoic acid 
• 888952-51-0 2-amino-5-fluoro-N'-(2-fluorophenyl)benzohydrazide 

Downstream Products

• 888951-64-2 C₁₉H₁₉F₂N₃O 
• 1050211-07-8 (S)-3-[5-fluoro-1-(2-fluoro-phenyl)-1H-indazol-3-yloxymethyl]-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain

The genetic validation for the role of the Nav1.7 voltage-gated ion channel in pain signaling pathways makes it an appealing target for the potential development of new pain drugs. The utility of nonselective Nav blockers is often li

Copper-catalyzed synthesis of substituted indazoles from 2-chloroarenes at low catalyst-loading

An efficient and convenient access to 1-substituted indazol-3-ones 2 has been achieved throughout the intramolecular C-N bond formations of 2-chloro-benzoic acid-N′-aryl and alkyl-hydrazides employing 0.5 mol% of cuprous (I) iodide and 20 mol% of l-prolin

The synthesis of (S)-5-fluoro-1-(2-fluorophenyl)-3-(piperidin-3-ylmethoxy)- 1H-indazole, a norepinephrine/serotonin reuptake inhibitor for the treatment of fibromyalgia

Compound 1, a norepinephrine/serotonin reuptake inhibitor (NSRI) for the treatment of fibromyalgia, has been synthesized in optically pure form in six linear steps and 48% overall yield with no chromatography. This route features a novel and efficient intramolecular cyclization to generate the indazolone core via a diazotization reaction and the preparation of a stable polymorph of the tartaric acid salt as the desired final form. The original synthetic route has been modified to avoid the use of toxic and expensive reagents, thus enabling the preparation of multigram quantities of API for toxicology studies.

Therapeutic pyrazolo[3,4-B]pyridines and indazoles

The present invention provides for compounds of Formula I: wherein R2, R3, R4, R5, R6, R7, X, and L have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of central nervous disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, anxiety, depression, and schizophrenia and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.